ELEVATE UC 40 JAPAN: Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Japanese Subjects

A Phase 3, Double-Blind, Placebo-Controlled, 40-Week Extension Study to Assess the Efficacy and Safety of Etrasimod in Japanese Subjects with Moderately to Severely Active Ulcerative Colitis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2071200080

Enrollment

Registered

2021-01-13

Start date

2020-12-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

The investigational drug and the placebo are an oral tablet. The investigational drug is APD334 (etrasimod).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Must have completed the Week 12 visit of Study APD334-302

Exclusion criteria

Exclusion criteria: 1. If the Investigator considers the subject to be unsuitable for any reason to participate in the study 2. Subjects requiring partial or total colectomy during the APD334-302 study 3. Subjects requiring treatment with prohibited concomitant medications

Design outcomes

Primary

Measure	Time frame
Proportion of participants achieving clinical remission	—

Contacts

Public ContactjRCT Inquiry Contact IQVIA Services Japan K.K.

IQVIA Services Japan K.K.

JP_Arena_ELEVATE_UC@iqvia.com+81-3-6859-9500

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026